ORC
GSK icon

O'Rourke & Company’s GSK GSK Stock Holding History

O'Rourke & Company’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-20,146
Closed -$864K – 144
2024
Q1 		$864K Sell
20,146
-2,894
-13% -$119K 0.5% 45
2023
Q4 		$854K Hold
23,040
– – 0.55% 42
2023
Q3 		$835K Sell
23,040
-4,316
-16% -$153K 0.61% 38
2023
Q2 		$975K Hold
27,356
– – 0.68% 32
2023
Q1 		$973K Hold
27,356
– – 0.74% 32
2022
Q4 		$961K Buy
27,356
+1,104
+4% +$36.8K 0.76% 34
2022
Q3 		$773K Buy
26,252
+3,242
+14% +$123K 0.67% 39
2022
Q2 		$1.25M Buy
23,010
+262
+1% +$14.5K 1.06% 25
2022
Q1 		$1.24M Buy
22,748
+1,660
+8% +$90.2K 0.85% 29
2021
Q4 		$1.16M Buy
+21,088
New +$1.1M 0.77% 31

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

O'Rourke & Company's GSK Position: Q2 2024 in Review

O'Rourke & Company sold out of GSK (GSK) in Q2 2024, closing a stake of 20,146 shares — an estimated $864K sold.

O'Rourke & Company first reported a position in GSK in Q4 2021 and held it in 10 quarters. The position peaked at $1.25M in Q2 2022. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

  • O'Rourke & Company reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
  • O'Rourke & Company sold 20,146 GSK shares in Q2 2024, an estimated $864K.
  • O'Rourke & Company first reported a position in GSK in Q4 2021 and held it in 10 quarters.
  • O'Rourke & Company's GSK position peaked at $1.25M in Q2 2022.
  • 884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on O'Rourke & Company's 13F filing for Q2 2024, filed 18 Jul 2024.